$NBIX
NEUROCRINE BIOSCIENCES INC

2022 Q1 Form 10-Q Financial Statement

#000091447522000022 Filed on May 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $310.6M $236.6M
YoY Change 31.28% -0.21%
Cost Of Revenue $4.600M $2.900M
YoY Change 58.62% 38.1%
Gross Profit $306.0M $233.7M
YoY Change 30.94% -0.55%
Gross Profit Margin 98.52% 98.77%
Selling, General & Admin $200.7M $129.0M
YoY Change 55.58% 9.51%
% of Gross Profit 65.59% 55.2%
Research & Development $102.2M $73.20M
YoY Change 39.62% 25.56%
% of Gross Profit 33.4% 31.32%
Depreciation & Amortization $3.300M $2.500M
YoY Change 32.0% 19.05%
% of Gross Profit 1.08% 1.07%
Operating Expenses $302.9M $202.2M
YoY Change 49.8% 13.47%
Operating Profit $3.100M $31.50M
YoY Change -90.16% -46.52%
Interest Expense $2.600M $6.400M
YoY Change -59.38% -21.95%
% of Operating Profit 83.87% 20.32%
Other Income/Expense, Net $18.30M -$4.300M
YoY Change -525.58% -78.5%
Pretax Income $21.40M $27.20M
YoY Change -21.32% -30.08%
Income Tax $7.500M -$4.900M
% Of Pretax Income 35.05% -18.01%
Net Earnings $13.90M $32.10M
YoY Change -56.7% -14.17%
Net Earnings / Revenue 4.48% 13.57%
Basic Earnings Per Share $0.15 $0.34
Diluted Earnings Per Share $0.14 $0.33
COMMON SHARES
Basic Shares Outstanding 95.30M shares 94.20M shares
Diluted Shares Outstanding 97.60M shares 98.20M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $664.9M $873.7M
YoY Change -23.9% 13.22%
Cash & Equivalents $270.2M $352.6M
Short-Term Investments $394.7M $521.1M
Other Short-Term Assets $60.80M $33.80M
YoY Change 79.88% 26.59%
Inventory $29.00M $30.10M
Prepaid Expenses
Receivables $263.5M $147.8M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.018B $1.085B
YoY Change -6.19% 12.1%
LONG-TERM ASSETS
Property, Plant & Equipment $63.90M $45.30M
YoY Change 41.06% 8.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $632.3M $288.5M
YoY Change 119.17% 4.79%
Other Assets $10.10M $1.400M
YoY Change 621.43% -56.25%
Total Long-Term Assets $1.126B $761.0M
YoY Change 48.0% 93.29%
TOTAL ASSETS
Total Short-Term Assets $1.018B $1.085B
Total Long-Term Assets $1.126B $761.0M
Total Assets $2.145B $1.846B
YoY Change 16.14% 35.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $235.9M $171.9M
YoY Change 37.23% 36.54%
Accrued Expenses $16.90M $12.20M
YoY Change 38.52% 38.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $253.5M $190.0M
YoY Change 33.42% 35.42%
LONG-TERM LIABILITIES
Long-Term Debt $377.7M $322.0M
YoY Change 17.3% -22.24%
Other Long-Term Liabilities $19.70M $21.30M
YoY Change -7.51% -1.39%
Total Long-Term Liabilities $19.70M $21.30M
YoY Change -7.51% -1.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $253.5M $190.0M
Total Long-Term Liabilities $19.70M $21.30M
Total Liabilities $753.4M $640.8M
YoY Change 17.57% 295.8%
SHAREHOLDERS EQUITY
Retained Earnings -$547.4M -$693.3M
YoY Change -21.04%
Common Stock $1.948B $1.898B
YoY Change 2.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.391B $1.206B
YoY Change
Total Liabilities & Shareholders Equity $2.145B $1.846B
YoY Change 16.14% 35.58%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $13.90M $32.10M
YoY Change -56.7% -14.17%
Depreciation, Depletion And Amortization $3.300M $2.500M
YoY Change 32.0% 19.05%
Cash From Operating Activities -$40.50M $87.30M
YoY Change -146.39% 145.92%
INVESTING ACTIVITIES
Capital Expenditures $7.600M $4.500M
YoY Change 68.89% 246.15%
Acquisitions
YoY Change
Other Investing Activities -$24.00M $67.60M
YoY Change -135.5% 95.94%
Cash From Investing Activities -$31.60M $63.10M
YoY Change -150.08% 90.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.100M $15.20M
YoY Change -59.87% 153.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.100M $15.10M
YoY Change -59.6% 151.67%
NET CHANGE
Cash From Operating Activities -$40.50M $87.30M
Cash From Investing Activities -$31.60M $63.10M
Cash From Financing Activities $6.100M $15.10M
Net Change In Cash -$66.00M $165.5M
YoY Change -139.88% 121.55%
FREE CASH FLOW
Cash From Operating Activities -$40.50M $87.30M
Capital Expenditures $7.600M $4.500M
Free Cash Flow -$48.10M $82.80M
YoY Change -158.09% 142.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P13Y7M
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
0-22705
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12780 El Camino Real
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2022Q1 dei City Area Code
CityAreaCode
(858)
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
617-7600
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95576662 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
270200000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340800000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
394700000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
370500000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
263500000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
185500000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
29000000.0 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
30500000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
60800000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
45500000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
972800000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
541000000.0 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
1018200000 USD
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
325300000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
315100000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
560700000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
94700000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
97200000 USD
CY2022Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
91300000 USD
CY2021Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
63700000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63900000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58600000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10100000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4400000 USD
CY2022Q1 us-gaap Assets
Assets
2144500000 USD
CY2021Q4 us-gaap Assets
Assets
2072500000 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
235900000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
225800000 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17600000 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20000000.0 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
253500000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
245800000 USD
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
377700000 USD
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
335100000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102500000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105300000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19700000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12300000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
753400000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
698500000 USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95500000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95500000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94900000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94900000 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1947700000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2011400000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9300000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1700000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547400000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635800000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1391100000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1374000000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2144500000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2072500000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
310600000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236600000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4600000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2900000 USD
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
102200000 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
73200000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
200700000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
129000000.0 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
307500000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
205100000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3100000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
31500000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
2600000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
6400000 USD
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
19900000 USD
CY2021Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
700000 USD
CY2022Q1 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
1000000.0 USD
CY2021Q1 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
1400000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18300000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4300000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21400000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27200000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7500000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4900000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
32100000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7600000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-800000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6300000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31300000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95300000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94200000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98200000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1374000000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 USD
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7600000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000000.0 USD
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6100000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1391100000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1126200000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
32100000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-800000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32900000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15200000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1205600000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
32900000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
168 security
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
32100000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
37000000.0 USD
CY2022Q1 us-gaap Depreciation
Depreciation
3300000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
2500000 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3900000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
400000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
300000 USD
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
19900000 USD
CY2021Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
700000 USD
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-300000 USD
CY2021Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-6200000 USD
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
800000 USD
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2600000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
78000000.0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9300000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1500000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2100000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11500000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11000000.0 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
10700000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1700000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40500000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87300000 USD
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
192800000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93700000 USD
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
176500000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
161300000 USD
CY2022Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
7700000 USD
CY2021Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7600000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4500000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31600000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63100000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6100000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15200000 USD
CY2022Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
CY2021Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
100000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6100000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15100000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-66000000.0 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
165500000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344000000.0 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190300000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278000000.0 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355800000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2800000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16000000.0 USD
CY2022Q1 nbix Number Of Irish Subsidiaries
NumberOfIrishSubsidiaries
2 subsidiary
CY2022Q1 nbix Debt Securities Available For Sale Position Number Of Positions
DebtSecuritiesAvailableForSalePositionNumberOfPositions
174 security
CY2022Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
3000000 USD
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
2200000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 USD
CY2022Q1 us-gaap Investments
Investments
1305000000 USD
CY2021Q4 us-gaap Investments
Investments
1338900000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9200000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11200000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4400000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3600000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15400000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15700000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
29000000.0 USD
CY2022Q1 nbix Annual Rent Escalation Percentage
AnnualRentEscalationPercentage
0.03
CY2021Q4 us-gaap Inventory Net
InventoryNet
30500000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
270200000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
352600000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3200000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
278000000.0 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
355800000 USD
CY2022Q1 nbix Lessee Operating Lease Option Term To Construct Fifth Building
LesseeOperatingLeaseOptionTermToConstructFifthBuilding
P6Y
CY2022Q1 nbix Rent Abatement Period
RentAbatementPeriod
P10M
CY2022Q1 nbix Lessee Operating Lease Monthly Base Rent Per Square Foot
LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
6 USD
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 renewalOption
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 USD
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4100000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3400000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4000000.0 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2600000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
13000000.0 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17900000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
17400000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15900000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
15700000 USD
CY2022Q1 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
70400000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
150300000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
30900000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
119400000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16900000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102500000 USD
CY2022Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
17200000 USD
CY2022Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
33300000 USD
CY2022Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
41900000 USD
CY2022Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Five
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive
479700000 USD
CY2022Q1 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
2200000 USD
CY2021Q1 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
2200000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4200000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
2600000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
6400000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
32100000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95300000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94200000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98200000 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6000000.0 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2700000 shares

Files In Submission

Name View Source Status
0000914475-22-000022-index-headers.html Edgar Link pending
0000914475-22-000022-index.html Edgar Link pending
0000914475-22-000022.txt Edgar Link pending
0000914475-22-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gemdale-neurocrinexcomme.htm Edgar Link pending
gemdale-neurocrinexcomme001.jpg Edgar Link pending
gemdale-neurocrinexcomme002.jpg Edgar Link pending
gemdale-neurocrinexcomme003.jpg Edgar Link pending
gemdale-neurocrinexcomme004.jpg Edgar Link pending
gemdale-neurocrinexcomme005.jpg Edgar Link pending
gemdale-neurocrinexcomme006.jpg Edgar Link pending
gemdale-neurocrinexcomme007.jpg Edgar Link pending
gemdale-neurocrinexcomme008.jpg Edgar Link pending
gemdale-neurocrinexcomme009.jpg Edgar Link pending
gemdale-neurocrinexcomme010.jpg Edgar Link pending
gemdale-neurocrinexcomme011.jpg Edgar Link pending
gemdale-neurocrinexcomme012.jpg Edgar Link pending
gemdale-neurocrinexcomme013.jpg Edgar Link pending
gemdale-neurocrinexcomme014.jpg Edgar Link pending
gemdale-neurocrinexcomme015.jpg Edgar Link pending
gemdale-neurocrinexcomme016.jpg Edgar Link pending
gemdale-neurocrinexcomme017.jpg Edgar Link pending
gemdale-neurocrinexcomme018.jpg Edgar Link pending
gemdale-neurocrinexcomme019.jpg Edgar Link pending
gemdale-neurocrinexcomme020.jpg Edgar Link pending
gemdale-neurocrinexcomme021.jpg Edgar Link pending
gemdale-neurocrinexcomme022.jpg Edgar Link pending
gemdale-neurocrinexcomme023.jpg Edgar Link pending
gemdale-neurocrinexcomme024.jpg Edgar Link pending
gemdale-neurocrinexcomme025.jpg Edgar Link pending
gemdale-neurocrinexcomme026.jpg Edgar Link pending
gemdale-neurocrinexcomme027.jpg Edgar Link pending
gemdale-neurocrinexcomme028.jpg Edgar Link pending
gemdale-neurocrinexcomme029.jpg Edgar Link pending
gemdale-neurocrinexcomme030.jpg Edgar Link pending
gemdale-neurocrinexcomme031.jpg Edgar Link pending
gemdale-neurocrinexcomme032.jpg Edgar Link pending
gemdale-neurocrinexcomme033.jpg Edgar Link pending
gemdale-neurocrinexcomme034.jpg Edgar Link pending
gemdale-neurocrinexcomme035.jpg Edgar Link pending
gemdale-neurocrinexcomme036.jpg Edgar Link pending
gemdale-neurocrinexcomme037.jpg Edgar Link pending
gemdale-neurocrinexcomme038.jpg Edgar Link pending
gemdale-neurocrinexcomme039.jpg Edgar Link pending
gemdale-neurocrinexcomme040.jpg Edgar Link pending
gemdale-neurocrinexcomme041.jpg Edgar Link pending
gemdale-neurocrinexcomme042.jpg Edgar Link pending
gemdale-neurocrinexcomme043.jpg Edgar Link pending
gemdale-neurocrinexcomme044.jpg Edgar Link pending
gemdale-neurocrinexcomme045.jpg Edgar Link pending
gemdale-neurocrinexcomme046.jpg Edgar Link pending
gemdale-neurocrinexcomme047.jpg Edgar Link pending
gemdale-neurocrinexcomme048.jpg Edgar Link pending
gemdale-neurocrinexcomme049.jpg Edgar Link pending
gemdale-neurocrinexcomme050.jpg Edgar Link pending
gemdale-neurocrinexcomme051.jpg Edgar Link pending
gemdale-neurocrinexcomme052.jpg Edgar Link pending
gemdale-neurocrinexcomme053.jpg Edgar Link pending
gemdale-neurocrinexcomme054.jpg Edgar Link pending
gemdale-neurocrinexcomme055.jpg Edgar Link pending
gemdale-neurocrinexcomme056.jpg Edgar Link pending
gemdale-neurocrinexcomme057.jpg Edgar Link pending
gemdale-neurocrinexcomme058.jpg Edgar Link pending
gemdale-neurocrinexcomme059.jpg Edgar Link pending
gemdale-neurocrinexcomme060.jpg Edgar Link pending
gemdale-neurocrinexcomme061.jpg Edgar Link pending
gemdale-neurocrinexcomme062.jpg Edgar Link pending
gemdale-neurocrinexcomme063.jpg Edgar Link pending
gemdale-neurocrinexcomme064.jpg Edgar Link pending
gemdale-neurocrinexcomme065.jpg Edgar Link pending
gemdale-neurocrinexcomme066.jpg Edgar Link pending
gemdale-neurocrinexcomme067.jpg Edgar Link pending
gemdale-neurocrinexcomme068.jpg Edgar Link pending
gemdale-neurocrinexcomme069.jpg Edgar Link pending
gemdale-neurocrinexcomme070.jpg Edgar Link pending
gemdale-neurocrinexcomme071.jpg Edgar Link pending
gemdale-neurocrinexcomme072.jpg Edgar Link pending
gemdale-neurocrinexcomme073.jpg Edgar Link pending
gemdale-neurocrinexcomme074.jpg Edgar Link pending
gemdale-neurocrinexcomme075.jpg Edgar Link pending
gemdale-neurocrinexcomme076.jpg Edgar Link pending
gemdale-neurocrinexcomme077.jpg Edgar Link pending
gemdale-neurocrinexcomme078.jpg Edgar Link pending
gemdale-neurocrinexcomme079.jpg Edgar Link pending
gemdale-neurocrinexcomme080.jpg Edgar Link pending
gemdale-neurocrinexcomme081.jpg Edgar Link pending
gemdale-neurocrinexcomme082.jpg Edgar Link pending
gemdale-neurocrinexcomme083.jpg Edgar Link pending
gemdale-neurocrinexcomme084.jpg Edgar Link pending
gemdale-neurocrinexcomme085.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20220331.htm Edgar Link pending
nbix-20220331.xsd Edgar Link pending
nbix-20220331_cal.xml Edgar Link unprocessable
nbix-20220331_def.xml Edgar Link unprocessable
nbix-20220331_g1.jpg Edgar Link pending
nbix-20220331_htm.xml Edgar Link completed
nbix-20220331_lab.xml Edgar Link unprocessable
nbix-20220331_pre.xml Edgar Link unprocessable
nbix-2022331exhibit311.htm Edgar Link pending
nbix-2022331exhibit312.htm Edgar Link pending
nbix-2022331exhibit32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending